Nureca Limited
NSE: NURECA · Medical Equipment & Supplies · sector
₹310.20NSE close 2026-10-26
Key numbers
Market cap₹296 cr
Price₹310.20
52w high / low₹376 / ₹204
P/E63.0xSector median 20.2x
P/B1.6xSector median 2.6x
Book value₹196.9
Dividend yield–Sector median 0.24%
ROE2.5%Sector median 12.4%
ROCE5.3%Sector median 13.5%
OPM3.5%Sector median 13.8%
Debt / equity0.01xSector median 0.13x
EV/EBITDA36.6xSector median 16.4x
Interest cover9.8x
Current ratio4.88x
Sales growth 3y+9.7%Sector median +12.9%
Profit growth 3y–Sector median +4.1%
PEG3.95x
Last 12 months to Sep 2026, Consolidated. "Sector median" = middle value of 15 companies in Medical Equipment & Supplies (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹42 cr vs borrowings ₹1 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 9.8x in the last 12 months.
- Promoter holding rose by 5.71 percentage points in a year, to 70.68% (2026-09-30).
- Operating cash flow was below net profit in 3 of the last 5 years (FY25, FY24, FY22).
- Net loss in 2 of the last 8 quarters.
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 134% of net profit in the last 12 months.
- Debtor days went from 6 (FY24) to 19 (FY26).
- Dividend paid in 1 of the last 5 financial years.
- Price ₹310.20 on 2026-10-26: -17.5% from the 52-week high, +52.1% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹408.95 · low ₹207.99
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26 | 32 | 34 | 38 | 40 | 35 | 40 | 59 |
| EBITDA | -4 | 1 | -1 | 3 | 3 | -6 | 3 | 5 |
| OPM % | -15.2% | 3.8% | -1.6% | 8.7% | 8.2% | -16.3% | 8.5% | 8.9% |
| Other income | 1 | 2 | 3 | 2 | 2 | 1 | 2 | 1 |
| Net profit | -3 | 2 | 1 | 4 | 4 | -6 | 3 | 4 |
| EPS (₹) | -2.80 | 2.47 | 0.81 | 3.63 | 3.91 | -6.45 | 3.21 | 4.25 |
| Revenue YoY | +49.8% | +11.6% | +18.0% | +55.1% | ||||
| Profit YoY | – | -346.6% | +279.0% | +11.6% |
Consolidated figures where filed. Latest quarter Sep 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 256 | 111 | 92 | 110 | 147 | 174 |
| EBITDA | 56 | -15 | -10 | -8 | 0 | 6 |
| Net profit | 45 | -8 | -2 | 1 | 2 | 5 |
| EPS (₹) | 44.96 | -8.25 | -1.79 | 0.85 | 2.11 | 4.92 |
| Revenue growth | -56.4% | -17.4% | +19.3% | +34.0% | +33.7% | |
| Profit growth | -118.3% | – | – | +144.7% | +15.9% | |
| Dividend / share (₹) | 5.00 | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +9.7% | -7.2% | +33.7% |
| Net profit | – | -46.2% | +15.9% |
| EPS | – | -49.1% | – |
| Share price | – | +8.4% (2y) | +4.4% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 195 | 193 | 194 | 181 |
| Borrowings | – | 3 | 0 | 2 | 1 |
| Cash & equivalents | – | 130 | 139 | 47 | 42 |
| Total assets | – | 207 | 205 | 210 | 196 |
| Fixed assets | – | 3 | 3 | 5 | 11 |
| Capital work in progress | – | 0 | 0 | 0 | 0 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 4 | 2 | 3 | 8 |
| Inventory | – | 34 | 31 | 40 | 48 |
| Payables | – | 5 | 5 | 7 | 5 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 1 | 10 | -3 | -19 | 3 |
| Cash from investing | -3 | -16 | 18 | 8 | 14 |
| Cash from financing | -7 | -2 | -1 | -0 | -20 |
| Capex | 6 | 0 | 1 | 4 | 7 |
| Free cash flow | -5 | 10 | -4 | -23 | -4 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | -4.2% | -0.9% | 0.4% | 1.2% |
| ROCE % | – | -5.2% | -1.1% | 1.3% | 3.5% |
| Debtor days | – | 14 | 6 | 11 | 19 |
| Inventory days | – | 167 | 186 | 214 | 187 |
| Payable days | – | 24 | 31 | 35 | 20 |
| Cash conversion cycle (days) | – | 157 | 161 | 190 | 186 |
| Working capital days | – | 583 | 728 | 591 | 251 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 70.68% |
| FIIs | 0.22% |
| DIIs | 0.24% |
| of which Mutual funds | 0.00% |
| Public (non-institutions) | 28.86% |
| Quarter | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Jan 2026 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 64.30% | 64.33% | 64.97% | 64.97% | 68.09% | 68.09% | 68.09% | 70.68% |
| Promoter group | % |
|---|---|
| Saurabh Goyal | 70.08% |
| Smita Goyal | 0.60% |
| Payal Goyal | 0.00% |
| Aryan Goyal | 0.00% |
| Nectar Biopharma Private Limited | 0.00% |
31,719 shareholders. Pledged: – of promoter shares.
Peers in Medical Equipment & Supplies
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| POLYMED | ₹14,631 cr | 46.4x | 4.7x | 10.7% | 12.7% | 22.8% | +18.9% | 0.24% |
| MOLBIO | ₹14,360 cr | – | – | – | – | – | – | – |
| TARSONS | ₹1,587 cr | 142.7x | 2.5x | 1.8% | 4.1% | 26.8% | +14.3% | – |
| LAXMIDENTL | ₹945 cr | 30.4x | 3.9x | 13.7% | 13.4% | 14.0% | – | – |
| FISCHER | ₹856 cr | 11.2x | 2.2x | -0.8% | 11.6% | 13.6% | – | 0.04% |
| HSIL | ₹740 cr | 36.9x | 6.5x | 21.8% | 24.1% | 10.0% | – | – |
| FABTECH | ₹543 cr | 8.8x | 1.3x | 11.6% | 13.6% | 10.9% | – | – |
| PREVEST | ₹455 cr | 14.7x | 4.0x | 29.9% | 36.9% | 34.1% | +12.9% | 0.26% |
| NURECA | ₹296 cr | 63.0x | 1.6x | 2.5% | 5.3% | 3.5% | +9.7% | – |
| CHOKSI | ₹115 cr | 22.2x | 2.7x | 13.1% | 17.9% | 14.5% | +300.1% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2025-12-12 | Buyback | Buy Back |
| 2024-07-11 | Other | Annual General Meeting |
| 2023-07-13 | Other | Annual General Meeting |
| 2022-09-01 | Other | Annual General Meeting |
| 2022-07-13 | Other | Annual General Meeting |
| 2022-02-24 | Dividend | Interim Dividend - Rs 3 Per Share |
| 2021-09-21 | Dividend | Annual General Meeting/Dividend - Rs 2 Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Medical Equipment & Supplies |
| Sub-industry | Medical Equipment & Supplies |
| Symbol | NURECA |
| BSE code | 543264 |
| ISIN | INE0DSF01015 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.